The proposed study is An Open-Label, Dose Escalation Study to Assess the Safety, and
Pharmacodynamics (PD) signals of DUR 928 in Patients with AH. DUR-928 will be administered in
100 mL 5% dextrose or 0.9% sodium chloride by slow intravenous infusion over 2 hrs (50mL/h)
until entire dose is given at Day 1 and Day 4. If a patient meets the hospital discharge
criteria prior to the 2nd dose, the patient will receive only one dose of DUR-928 instead of
2 doses.
Phase:
Phase 2
Details
Lead Sponsor:
Craig James McClain
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)